Table 1.
Truncated O-glycans in human cancer.
| Positive/Total (% positive) | |||||||
|---|---|---|---|---|---|---|---|
| Tn | STn | T | |||||
| Breast cancer, total | 35/64 | (57%) | 22/68 | (33%) | 18/57 | (32%) | |
| Invasive ductal carcinoma | 32/55 | (58%) | 22/59 | (37%) | 15/48 | (31%) | |
| Medullary carcinoma | 3/9 | (33%) | 0/9 | (0%) | 3/9 | (33%) | |
| Colorectal cancer, total | 71/140 | (51%) | 112/140 | (80%) | 26/128 | (20%) | |
| Adenocarcinoma | 69/136 | (51%) | 110/135 | (81%) | 26/124 | (21%) | |
| Signet-ring cell carcinoma | 2/4 | (50%) | 2/4 | (50%) | 0/4 | (0%) | |
| Lung cancer, total | 13/80 | (16%) | 26/79 | (33%) | 8/79 | (10%) | |
| Adenocarcinoma | 2/17 | (12%) | 8/17 | (47%) | 1/16 | (6%) | |
| Bronchioloalveolar carcinoma | 1/9 | (11%) | 1/9 | (11%) | 1/9 | (11%) | |
| Large cell undifferentiated carcinoma | 2/8 | (25%) | 2/8 | (25%) | 1/8 | (13%) | |
| Papillary adenocarcinoma | 3/9 | (33%) | 6/9 | (67%) | 2/9 | (22%) | |
| Squamous cell carcinoma | 5/31 | (16%) | 10/31 | (32%) | 3/31 | (10%) | |
| Small cell carcinoma | 0/5 | (0%) | 0/4 | (0%) | 0/5 | (0%) | |
| Skin cancer, total | 13/39 | (33%) | 9/37 | (24%) | 6/24 | (25%) | |
| Squamous cell carcinoma | 4/18 | (22%) | 9/18 | (50%) | 4/15 | (27%) | |
| Basal cell carcinoma | 7/15 | (47%) | 0/15 | (0%) | 2/13 | (15%) | |
| Pancreatic cancer, total | 57/108 | (53%) | 60/108 | (56%) | 17/108 | (16%) | |
| Adenocarcinoma | 7/12 | (58%) | 8/12 | (67%) | 2/12 | (19%) | |
| Adenosquamous carcinoma | 5/6 | (83%) | 5/6 | (83%) | 0/6 | (0%) | |
| Duct adenocarcinoma | 36/54 | (67%) | 41/54 | (76%) | 10/54 | (19%) | |
| Islet cell tumour | 0/20 | (0%) | 0/20 | (0%) | 2/20 | (10%) | |
| Mucinous adenocarcinoma | 2/2 | (100%) | 2/2 | (100%) | 1/2 | (50%) | |
| Neuroendocrine tumour | 1/2 | (50%) | 0/2 | (0%) | 0/2 | (0%) | |
| Undifferentiated adenocarcinoma | 1/2 | (50%) | 0/2 | (0%) | 0/2 | (0%) | |
| Osteosarcoma, total | 0/8 | (0%) | N/D | 0/8 | (0%) | ||
| Chondroblastic | 0/4 | (0%) | 0/4 | (0%) | |||
| Osteoblastic | 0/4 | (0%) | 0/4 | (0%) | |||
| Bone marrow cancers | 0/8 | (0%) | 0/8 | (0%) | N/D | ||
| Plasma cell myeloma | 0/8 | (0%) | 0/8 | (0%) | |||
| Tumours of the CNS, total | 4/87 | (5%) | 1/75 | (1%) | 17/75 | (23%) | |
| Glioblastoma | 4/40 | (10%) | 0/40 | (0%) | 6/40 | (15%) | |
| Ependymoma | 0/16 | (0%) | 0/4 | (0%) | 2/4 | (50%) | |
| Astrocytoma | 0/15 | (0%) | 0/15 | (0%) | 6/15 | (40%) | |
| Oligoastrocytoma | 0/4 | (0%) | 0/4 | (0%) | 1/4 | (25%) | |
| Oligodendroglioma | 0/9 | (0%) | 1/9 | (11%) | 2/9 | (22%) | |
| Medulloblastoma | 0/3 | (0%) | 0/3 | (0%) | 0/3 | (0%) | |
Tn Thomsen-nouveau antigen, GalNAcα-Ser/Thr, STn sialyl-Tn antigen, Neu5Acα2–6GalNAcα -Ser/Thr. T Thomsen-Friedenreich antigen, Galβ1-3GalNAcα-Ser/Thr. N/D not determined, i.e. samples were not available for analysis.
The number of tumour cores classified as positive for Tn-, STn- or T-expression defined as (a) strong staining, (b) membranous accentuation and (c) >10 % of the tumour being strongly stained using IHC (before /) relative to the total number of tumour cores sampled (after /). The percentage of positive tumour cores is given in brackets. Bold values are aggregated results from all tumor core of a specific tumor type (e.g. “Breast cancer”) whereas results from tumor subclasses (e.g. “Medullary carcinoma”) are not bold.